Get notified when STTK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 47,487,573 Common Stock Warrants Outstanding As of March 31, 2026 (new) — The large warrant overhang could significantly dilute existing shareholders and pressure the stock price.
- Immediate Dilution of $2.08 Per Share to New Investors (new) — New investors pay $4.00 per share but receive shares with a pro forma net tangible book value of only $1.92, representing a 52% loss of value immediately.
Shattuck Labs prices $4.00/share offering of 10.9M shares and pre-funded warrants, raising $70.5M net for clinical trials
Filed June 11, 2026 · ~1 min read
Key Changes
-
high
Shattuck Labs is selling 10,879,376 common shares and pre-funded warrants for 7,870,624 shares at $4.00 per share, with net proceeds to the company of approximately $70.5 million.
The Offering verify on EDGAR → -
medium
The company intends to use net proceeds to advance ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $2.08 per share, or $2.24 per share if all pre-funded warrants are exercised, based on the $4.00 offering price.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.
Partner
Trade STTK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify